Patients must travel frequently to clinics and hospitals.
True neuroplasticity requires repetitive, targeted activity, which is difficult to maintain outside structured therapy.
Clinicians often see only snapshots of the patient’s condition, not the full day-to-day picture.
Every year more than 80 million people worldwide are affected by stroke, traumatic brain injury and multiple sclerosis
NeuroVAI™ is a non-invasive medical device that uses a soft, universally designed mouthpiece which adapts comfortably to different adult jaw shapes and rests under the tongue. It delivers optical stimulation with photobiomodulation (PBM) to the cranial nerves that connect the tongue to the brain. Short, guided sessions fit easily into daily life and are designed to support neuroplasticity in brain networks involved in movement, balance and cognition.
During each session, built-in biological sensors and smart electronics capture objective signals from the mouth and jaw area. This data is securely transmitted to the NeuroVAI™ cloud, where advanced AI algorithms analyze trends over time.
The goal: help clinicians and care teams more easily monitor recovery, identify meaningful changes early, and tailor treatment with greater precision.
The NeuroVAI™ app transforms complex data into clear, visual insights. Patients can easily track their progress through intuitive graphs, progress bars, and trend indicators that reflect changes over days and weeks. Clinicians access structured views of the same information, enabling data-driven conversations and more personalized decisions throughout each patient’s rehabilitation journey.
NeuroVAI™ is a non-invasive medical device that uses a soft, universally designed mouthpiece which adapts comfortably to different adult jaw shapes and rests under the tongue. It delivers optical stimulation with photobiomodulation (PBM) to the cranial nerves that connect the tongue to the brain. Short, guided sessions fit easily into daily life and are designed to support neuroplasticity in brain networks involved in movement, balance and cognition.
FreeN Medical – App Intelligent
With a monthly subscription, users gain access to AI-powered insights.
personalized health analytics, and continuous progress tracking.

Former PMO Senior Executive (24 years) with a proven track record in leading complex, large-scale, and resource-intensive projects. Former CEO of Decuver. Strategic representative for companies in the healthcare sector.


is a public health specialist, epidemiologist, and researcher, and the former Associate Director-General of the Israeli Ministry of Health. He brings extensive experience in healthcare leadership, regulation, and medical innovation, working closely with Biotech and HealthTech companies to navigate complex regulatory landscapes and drive growth.


An integrative medicine expert with extensive experience in neurological rehabilitation. Nadav completed extensive internships in China in internal medicine and neurology, and lectures professionally on integrative medicine. His clinical experience with complex neurological patients inspired the creation of NeuroVAI™ and FreeN Medical Innovation.


A senior electrical engineer with over 20 years of experience in the Israeli high-tech ecosystem, Eyal has led multidisciplinary projects that span electronics, embedded systems, software and communications. At FreeN Medical Innovation, he is responsible for the architecture and development of the NeuroVAI™ hardware, firmware and connectivity.


Product Design & Human Factors Ela is a designer and design researcher with a Master’s degree in Medical Device Design (Technion) and a PhD in Human Factors Engineering (Ben-Gurion University). She ensures that NeuroVAI™ is not only technologically sophisticated, but also ergonomically optimized, intuitive and safe for daily home use.


Consulting, Regulatory Affairs Tal is a regulatory and clinical strategy expert specializing in medical devices. She supports FreeN Medical Innovation in defining the regulatory roadmap, quality management processes and clinical evidence strategy required to bring NeuroVAI™ to market safely and efficiently.
